Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 354-368

  Cassano, Tommaso ^a   Carratù, M Rosaria ^a   Coluccia, Addolorata ^a   Di Giovanni, Vincenzo ^a   Steardo, Luca ^b   Cuomo, Vincenzo ^c   Trabace, Luigia ^d  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; CHF2819; Neurotransmitters; Rat hippocampus

Indexed keywords

1,2,3,3A,8,8A HEXAHYDRO 1,3A,8 TRIMETHYLPYRROLO[2,3 B]INDOL 5 OL 2'ETHYLPHENYLCARBAMATE N OXIDE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ARGININE; ASPARTIC ACID; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITRULLINE; DOPAMINE; GANSTIGMINE; GLUTAMIC ACID; NORADRENALIN; SCOPOLAMINE; SEROTONIN; TAURINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; HIPPOCAMPUS; INVOLUNTARY MOVEMENT; NEUROTRANSMISSION; NONHUMAN; PASSIVE AVOIDANCE; PATHOGENESIS; REVIEW;

EID: 0036660009     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10088     Document Type: Review

References (107)

1. Aletrino MA, Vogels OJ, Van Domburg PH, Ten Donkelaar HJ. 1992. Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiol Aging 13:461-468.
2. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. 1988. Differential alteration of various cholinergic-markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50:1914-1923.
3. Arias RL, Tasse JR, Bowlby MR. 1999. Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Brain Res 816:299-308.
4. Astier A, Petitjean D. 1985. Pharmacokinetics of an anticholinesterasic agent (eserin N-oxide) in humans after administration of two galenic forms. J Pharm Clin 4:521-527.
5. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
6. Beal MF, MacGarvey U, Swartz KJ. 1990. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease. Ann Neurol 28:157-161.
7. Beani L, Tanganelli S, Antonelli T, Bianchi C. 1986. Noradrenergic modulation of cortical acethylcoline release in both direct and γ-aminobutyric acid-mediated. J Pharmacol Exp Ther 236:230-236.
8. Begley JG, Duan W, Chan S, Duff K, Mattson MP. 1999. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem 72:1030-1039.
9. Bianchi C, Tanganelli S, Marzola G, Beani L. 1982. GABA-induced changes in acetylcholine release from slices of guinea-pig brain. Naunyn-Schmiedeberg's Arch Pharmacol 318:253-258.
10. Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CC, Spillane JA, Esiri MM, Neary D, Snowdon JS, Wilcock GK, Davison AN. 1983. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 41:266-272.
11. Bredt DS, Hwang PM, Snyder SH. 1990. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347:768-770.
12. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. 1999. The effects of donepezil in Alzheimer's disease: Results from a multinational trials. Dement Geriatr Cog Disord 10:237-244.
13. 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124:347-354.
14. Carlson MD, Penney JB Jr, Young AB. 1993. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiol Aging 14:343-352.
15. Chabrier PE, Demerle-Pallardy C, Auguet M. 1999. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Cell Mol Life Sci 55:1029-1035.
16. Chan-Palay V, Asan E. 1989. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287:373-392.
17. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
18. Chu DCM, Penney JB, Young AB. 1987. Quantitative autoradiography of hippocampal GABAb and GABAa receptor changes in Alzheimer's disease. Neurosci Lett 82:246-252.
19. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JA. 1984. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43:1574-1581.
20. Csernansky JG, Bardgett ME, Sheline YI, Morris JC, Olney JW. 1996. CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology 46:1715-1720.
21. Cuadra G, Giacobini E. 1995. Coadministration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 273:230-240.
22. Cuadra G, Summers K, Giacobini E. 1994. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 270:277-284.
23. Cummings JL. 2000. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157:4-15.
24. Dajas-Bailador F, Costa G, Emmett S, Bonilla C, Dajas F. 1996. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum in vivo. Brain Res 722:12-18.
25. Damsma G, Westerink BH, de Boer P, de Vries JB, Horn AS. 1988. Basal acetylcholine release in freely moving rats detected by online trans-striatal dialysis: Pharmacological aspects. Life Sci 43:1161-1168.
26. Davies P. 1999. Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 281:1433-1434.
27. Davies P, Maloney AJ. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
28. Day J, Fibiger HC. 1992. Dopaminergic regulation of cortical acetylcholine release. Synapse 12:281-286.
29. de Boer P, Westerink BH, Horn AS. 1990. The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses. Neurosci Lett 116:357-360.
30. Decker MW, McGaugh JL. 1991. The role of interactions between cholinergic systems and other neuromodulatory systems in learning and memory. Synapse 7:151-168.
31. Deutsch JA. 1973. The cholinergic synapse and the site of memory. In: Deutsch JA, editor. The physiological basis of memory. New York: Academic Press. p 13-16.
32. Dewar D, Chalmers DT, Graham DI, McCulloch J. 1991. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus. Brain Res 553:58-64.
33. Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. 1999. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriat Psychiatry 14:973-982.
34. Faber-Langendoen K, Morris JC, Knesevich JW, LaBarge E, Miller JP, Berg L. 1988. Aphasia in senile dementia of the Alzheimer type. Ann Neurol 23:365-370.
35. Folstein MF, Bylsma FW. 1994. In: Terry RD, Catsman R, Bick KL editors. Alzheimer's Disease. New York: Raven Press. p 27-40.
36. Friedland RP. 1993. Alzheimer's disease: clinical features and differential diagnosis. Neurology 43:S45-S51.
37. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. 1996. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry 39:82-91.
38. Geula C, Mesulam MM. 1994. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL editors. Alzheimer's Disease. New York: Raven Press. p 263-291.
39. Giacobini E, Zhu XD, Williams E, Sherman KA. 1996. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35:205-211.
40. Gottfries CG. 1990. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J Neural Transm (Suppl) 30:33-43.
41. Gottfries CG. 1996. Depression and Alzheimer's disease. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston: Birkäuser. p 495-499.
42. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B. 1983. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4:261-271.
43. Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A. 1995. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 15:3-31.
44. Grenhoff J, Svensson TH. 1992. Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine. Naunyn-Schmiedeberg's Arch Pharmacol 346:395-398.
45. Haroutunian V, Santucci AC, Davis KL. 1990. Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. Prog Brain Res 84:333-346.
46. Hoyer S, Nitsch R. 1989. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 75:227-232.
47. Hyman BT, Van Hoesen GW, Damasio AR. 1987. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 22:37-40.
48. Ikari H, Spangler EL, Greig NH, Pei XF, Brossi A, Speer D, Patel N, Ingram DK. 1995. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport 6:481-484.
49. Imbimbo BP. 2001. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15:375-390.
50. Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. 1999. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 52:700-708.
51. Itoh A, Nitta A, Katono Y, Usui M, Naruhashi K, Iida R, Hasegawa T, Nabeshima T. 1997. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. Eur J Pharmacol 322:11-19.
52. Kawashima K, Hayakawa T, Kashima Y, Suzuki T, Fujimoto K, Oohata H. 1991. Determination of acetylcholine release in the striatum of anesthetized rats using in vivo microdialysis and a radioimmunoassay. J Neurochem 57:882-887.
53. Kelly JS. 1999. Alzheimer's disease: the tacrine legacy. Trends Pharmacol Sci 20:127-129.
54. KendricK KM, Guevara-Guzman R, de la Riva C, Christensen J, Ostergaard K, Emson P. 1996. NMDA and Kainate-evoked release of nitric oxide and classical transmitters in the rat striatum: in vivo evidence that nitric oxide may play a neuroprotective role. Eur J Neurosci 8:2619-2634.
55. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. 1994. A 30-week randomized controlled trial of highdose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271:985-991.
56. Koh JY, Yang LL, Cotman CW. 1990. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533:315-320.
57. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. 1999. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 72:310-317.
58. Kowall NW, Beal MF. 1991. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillay tangles in Alzheimer's disease. Ann Neurol 29:162-167.
59. Law A, Gauthier S, Quirion R. 2001. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Brain Res Rev 35:73-96.
60. Lowe SL, Bowen DM, Francis PT, Neary D. 1990. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38:571-577.
61. Maragos WF, Greenamyre JT, Penny JB, Young AB. 1987. Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci 10:65-68.
62. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. 1996. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40:759-766.
63. May N. 1993. Brain banks and research in neurochemistry. J Neural Transm 39:119-126.
64. Memo M, Missale C, Trivelli L, Spano PF. 1988. Acute scopolamine treatment decreases dopamine metabolism in rat hippocampus and frontal cortex. Eur J Pharmacol 149:367-370.
65. Messamore E, Ogane N, Giacobini E. 1993. Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum. Neuropharmacology 32:291-296.
66. Mori F, Cuadra G, Giacobini E. 1995. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 20:1081-1088.
67. Moser VC. 1997. Neurobehavioral screening battery. Neurotoxicology 18:923-1083.
68. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, Yamaguchi S, Kawabata S, Okada M. 1998. Glutamate receptors: brain function and signal transduction. Brain Res Rev 26:230-235.
69. Nielsen JA, Mena EE, Williams IH, Nocerini MR, Liston D. 1989. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 173:53-64.
70. Nordberg A, Alafuzoff I, Winblad B. 1986. Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. Neurosci Lett 70:160-164.
71. Nyth AL, Gottfries CG. 1990. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disordes. A Nordic multicentre study. Br J Psychiatry 157:894-901.
72. Pepeu G. 2000. Preclinical pharmacology of cholinesterase inhibitors. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Publishers. p 145-155.
73. Perola E, Cellai L, Lambda D, Filocamo L, Brufani M. 1997. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. Biochim Biophys Acta 1343:41-50.
74. Perry EK. 1986. The cholinergic hypothesis-ten years on. Br Med Bull 42:63-69.
75. Pietra C, Villetti G, Bolzoni PT, Delcanale M, Amari G, Caruso P, Civelli M. 1999. Cholinesterase inhibitory activity of new geneserine derivatives. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, editors. Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons. p 689-696.
76. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70.
77. Quirion R. 1993. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. J Psychiatry Neurosci 18:226-234.
78. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. 1999. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J Clin Psychiatry 60:318-325.
79. Robinson B, Robinson JB. 1968. The anti-cholinesterase activities of the alkaloids of Physostigma venenosum seeds. J Pharm Pharmacol 20:213-217.
80. Robinson TN, de Souza RJ, Cross AJ, Green AR. 1989. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br J Pharmacol 98:1127-1136.
81. Rogers J, Morrison JH. 1985. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 5:2801-2808.
82. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318:633-638.
83. Scali C, Giovannini MG, Bartolini L, Prosperi C, Hinz V, Schmidt B, Pepeu G. 1997a. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 325:173-180.
84. Scali C, Giovannini MG, Prosperi C, Bartolini L, Pepeu G. 1997b. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res 36:463-469.
85. Schneider LS. 1998. Cholinergic deficiency in Alzheimer's disease. Pathogenic model. Am J Geriatr Psychiatry 6(Suppl 1):S49-55.
86. Schneider LS. 2001. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med 17:337-358.
87. Siegfried K. 1995. The efficacy of cholinergic drugs in patients with Alzheimer's disease-Focus on the aminoacridines. Hum Psychopharmacol 10:89-96.
88. Sugaya K, Giacobini E, Chiappinelli VA. 1990. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J Neurosci Res 27:349-359.
89. Svensson AL, Warpman U, Hellstrom-Lindahl E, Bogdanovic N, Lannfelt L, Nordberg A. 1997. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E. genotypes. Neurosci Lett 232:37-40.
90. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. 2000. A 5-month, randomized placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269-2276.
91. Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. 1999. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 52:1146-1152.
92. Torreilles F, Salman-Tabcheh S, Guerin M, Torreiles J. 1999. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Rev 30:153-163.
93. Trabace L, Kendrick KM. 2000. Nitric oxide can differentially modulate striatal neurotransmitter concentrazione via soluble guanylate cyclase and peroxynitrite formation. J Neurochem 75:1664-1674.
94. Trabace L, Cassano T, Steardo L, Pietra C, Villetti G, Kendrick K, Cuomo V. 2000a. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's Disease. J Pharmacol Exp Ther 294:187-194.
95. Trabace L, Coluccia A, Gaetani S, Tattoli M, Cagiano R, Pietra C, Kendrick M, Cuomo V. 2000b. In vivo neurochemical effects of acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res 865:268-271.
96. Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Kendrick KM, Cuomo V. 2001. Effects of ENA713 and CHF2819, two antiAlzheimer's disease drugs, on rat amino acid levels. Brain Res 910:182-186.
97. Trabace L, Cassano T, Loverre A, Steardo L, Cuomo V. 2002. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor. CNS Drug Rev 8:53-69.
98. Vaucher E, Linville D, Hamel E. 1997. Cholinergic basal forebrain projections to nitric oxide synthase-containing neurons in the rat cerebral cortex. Neuroscience 79:827-836.
99. Wang T, Tang C. 1998. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137-142.
100. Warpman U, Zhang X, Nordberg A. 1996. Effect of tacrine on in vivo release of dopamine and its metabolites in the striatum of freely moving rats. J Pharmacol Exp Ther 277:917-922.
101. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. 1991. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 48:278-281.
102. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ. 1988. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45:722-724.
103. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321:1445-1449.
104. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P and Donepezil Nordic Study Group. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57:489-495.
105. Xu M, Mizobe F, Yamamoto T, Kato T. 1989. Differential effects of M1 and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain Res 495:232-242.
106. Zubenko GS, Moossy J, Martinez AJ, Rao GR, Kopp U, Hanin I. 1989. A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease. Arch Neurol 46:634-638.
107. Zubenko GS, Mossy J, Kopp U. 1990. Neurochemical correlates of major depression in primary dementia. Arch Neurol 47:209-214.